• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Epix lands drug-discovery partner

Article

Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry

Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry laboratories owned by NeoGenesis that enable the rapid screening of compounds that could be used to form new products. Epix hopes the deal will enable it to find new advanced MRI contrast agents.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.